Related Experiment Videos
Participants in HIV clinical trials in Europe
W Schrooten1, M Borchert, C Dreezen
1Institute of Tropical Medicine, Antwerp, Belgium.
International Journal of STD & AIDS
|March 10, 2001
Summary
Most people with HIV in Europe are willing to join clinical trials, but ethical standards and communication need improvement. Many trials are not proposed, and follow-up information is often lacking.
Area of Science:
- Clinical Medicine
- Public Health
- Medical Ethics
Background:
- Antiretroviral therapies for HIV have expanded, necessitating more clinical trials to optimize treatment.
- Understanding participant profiles and experiences in HIV clinical trials is crucial for future research.
Purpose of the Study:
- To investigate the characteristics of participants in human immunodeficiency virus (HIV) clinical trials across Europe.
- To gather insights into the experiences and perspectives of individuals participating in HIV research.
Main Methods:
- Anonymous, self-administered questionnaires were distributed to individuals with HIV infection in 11 European countries between August 1996 and September 1997.
- Data were collected from 1,366 participants, yielding a 50% response rate.
Main Results:
- 31% of respondents had prior experience in at least one HIV clinical trial, with participation rates varying significantly across European regions (12%-61%).
- Higher participation was noted in Northern/Central Europe compared to Southern Europe (40% vs. 18%) and among individuals with higher incomes.
- While 92% felt well-informed before enrollment, 4% lacked written consent, and 22% felt pressured; only 21% received study outcome information.
Conclusions:
- A majority of individuals with HIV in European treatment centers express willingness to participate in clinical trials.
- There is a need for stricter adherence to universal ethical standards in European HIV clinical trials.
- Lack of trial proposal and inadequate outcome communication are significant barriers to participation.